New €5 million project to transform care for multimorbid patients launched

June 01, 2016

Care for patients with multimorbid chronic conditions could be transformed by a new cloud infrastructure to be developed at the University of Warwick's Institute of Digital Healthcare based at WMG, as part of a European project.

The system called C3-Cloud, which is led by the Institute of Digital Healthcare aims to transform current care models which are mostly fragmented, addressing chronic conditions in isolation. The researchers have been awarded EUR 5 Million to lead pilots of the system in three countries. Funded by EU Horizon 2020, 12 partners in seven countries are combining their expertise to improve care provided to patients with multimorbidity.

Patients with multimorbidity have two or chronic conditions such as diabetes, dementia and arthritis which makes treatment more complicated and has become more prevalent among older adults as mortality rates have declined and the population has aged.

Professor Arvanitis Head of Research at the Institute of Digital Healthcare, WMG, University of Warwick and C3-Cloud project co-ordinator said: "The models used at the moment considerably limit the quality of care to patients, results in safety risks when treatments for each condition are not compatible with each other, and increases cost.

"This happens mainly due to avoidable readmissions to hospitals, as well as repeated visits to the various experts. C3-Cloud is a patient-centric approach, considering the unique circumstances of each patient, taking into account all their conditions and needs."

For the first time the system will allow for the creation of a personalised treatment plan for each patient by allowing hospitals, general practitioners and social care organisations across the health and care system to exchange information and coordinate care more effectively. The project will contribute to significant research breakthroughs in healthcare such as the introduction of new models of patient-centric, integrated care, and the development of automated IT supported clinical decision making which will prevent incompatible treatment plans.

C3-Cloud, which will run from for four years, involves 12 partners from six EU member states and one associated country (Turkey) and will include public health providers, industry, and research organisations. Other partners are: Software Research, Development and Consultancy Corp.(SRDC) Turkey; Institut national de la santé et de la recherché médicale (Inserm), France; European Institute for Health Records, (EuroRec) France; Empirica, Germany; Medixine, Finland; South Warwickshire NHS Foundation Trust, UK; Osakidetza - Servicio Vasco de Salud, Spain; Kronikgune, Spain; Örebro University, Sweden; Region Jämtland Härjedalen, Sweden; and Cambio Healthcare Systems, Sweden.

The project will include three 15 month long pilots, which will be conducted in the Warwickshire region of UK, in the Basque Country in Spain and in the Jämtland Härjedalen region of Sweden. To demonstrate feasibility the trials will focus on diabetes, heart failure, renal failure and depression in different comorbidity combinations. The three European areas have been chosen because of their varied health, social care and technology systems in place. The comparisons will enhance the study's evidence base on health outcomes and efficiency gains. Eventually it is hoped that the system will be rolled out across Europe allowing patients with chronic multimorbidity to benefit from improved health and care.

Professor Arvanitis added: "The personalised care plans will be developed through systematic and semi-automatic reconciliation of clinical guidelines, and will incorporate risk prediction and stratification, recommendation reconciliation, poly-pharmacy management and goal setting. Active patient involvement and treatment adherence will be achieved through a Patient Empowerment Platform ensuring patient needs are respected in decision making and taking into account preferences and psychosocial aspects."

The Institute of Digital Healthcare, based at WMG, University of Warwick is a collaboration between WMG, Warwick Medical School, and the NHS, aiming to improve people's health and wellbeing by developing innovative digital technologies and services. Through cutting edge R&D and world class postgraduate education, the aim is to improve the quality, safety, accessibility, and productivity of healthcare for clinicians, patients and carers.

University of Warwick

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to